Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
复制标题
DOI：
10.1016/j.dsx.2021.05.019
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Misra A
中科院分区：
文献类型：
--
作者：
Singh AK;Singh R;Joshi SR;Misra A
在2019冠状病毒病（COVID-19）患者中，鼻眶毛霉菌病的病例报告越来越多，特别是来自印度的病例。糖尿病（DM）是严重COVID-19和毛霉菌病的独立风险因素。我们的目标是对文献进行系统回顾，以了解患有毛霉菌病和COVID-19的患者的特征。我们使用关键词检索了PubMed和Google Scholar的电子数据库，从开始到2021年5月13日。我们检索了全球范围内报告的毛霉菌病和COVID-19病例报告/患者系列的所有详细信息。随后，我们分析了COVID-19患者的患者特征、相关合并症、毛霉菌病的部位、类固醇的使用及其结局。总体而言，已报告101例COVID-19感染者的毛霉菌病病例，其中82例来自印度，19例来自世界其他地区。毛霉菌病主要见于男性（78.9%），无论是在COVID-19活动期（59.4%）还是康复期（40.6%）。80%的病例存在既存糖尿病（DM），而14.9%的病例存在伴随糖尿病酮症酸中毒（DKA）。76.3%的病例记录了用于治疗COVID-19的皮质类固醇摄入。毛霉菌病以鼻和鼻窦最常见（88.9%），其次是鼻眶（56.7%）。死亡率为30.7%。糖尿病的邪恶Trinity，在COVID-19的背景下广泛使用皮质类固醇似乎增加了毛霉菌病。COVID-19患者应尽一切努力维持最佳血糖水平，仅明智使用皮质类固醇。
There are increasing case reports of rhino-orbital mucormycosis in people with coronavirus disease 2019 (COVID-19), especially from India. Diabetes mellitus (DM) is an independent risk factor for both severe COVID-19 and mucormycosis. We aim to conduct a systematic review of literature to find out the patient's characteristics having mucormycosis and COVID-19. We searched the electronic database of PubMed and Google Scholar from inception until May 13, 2021 using keywords. We retrieved all the granular details of case reports/series of patients with mucormycosis, and COVID-19 reported world-wide. Subsequently we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, use of steroids and its outcome in people with COVID-19. Overall, 101 cases of mucormycosis in people with COVID-19 have been reported, of which 82 cases were from India and 19 from the rest of the world. Mucormycosis was predominantly seen in males (78.9%), both in people who were active (59.4%) or recovered (40.6%) from COVID-19. Pre-existing diabetes mellitus (DM) was present in 80% of cases, while concomitant diabetic ketoacidosis (DKA) was present in 14.9%. Corticosteroid intake for the treatment of COVID-19 was recorded in 76.3% of cases. Mucormycosis involving nose and sinuses (88.9%) was most common followed by rhino-orbital (56.7%). Mortality was noted in 30.7% of the cases. An unholy trinity of diabetes, rampant use of corticosteroid in a background of COVID-19 appears to increase mucormycosis. All efforts should be made to maintain optimal glucose and only judicious use of corticosteroids in patients with COVID-19.
登录
查看更多内容
影响因子：
14.2
作者：
Patel, A.;Kaur, H.;Chakrabarti, A.
通讯作者：
Chakrabarti, A.
影响因子：
6.7
作者：
Baldin C;Ibrahim AS
通讯作者：
Ibrahim AS
DOI：
10.3390/jof7030174
发表时间：
2021-02-28
期刊：
Journal of fungi (Basel, Switzerland)
影响因子：
--
作者：
Kanwar A;Jordan A;Olewiler S;Wehberg K;Cortes M;Jackson BR
通讯作者：
Jackson BR
DOI：
10.1001/jama.1957.02970450007003
发表时间：
1957-01-01
影响因子：
120.7
作者：
BAKER, RD
通讯作者：
BAKER, RD
影响因子：
2.9
作者：
Bala, Kiran;Chander, Jagdish;Attri, Ashok Kumar
通讯作者：
Attri, Ashok Kumar